Prudential Financial Inc. Acquires Shares of 10,160 Anavex Life Sciences Corp. (NASDAQ:AVXL)

Prudential Financial Inc. bought a new position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 10,160 shares of the biotechnology company’s stock, valued at approximately $109,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of AVXL. Barclays PLC increased its position in shares of Anavex Life Sciences by 70.4% during the third quarter. Barclays PLC now owns 155,179 shares of the biotechnology company’s stock valued at $882,000 after acquiring an additional 64,101 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new position in Anavex Life Sciences in the 4th quarter valued at $243,000. Charles Schwab Investment Management Inc. increased its position in shares of Anavex Life Sciences by 2.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 665,976 shares of the biotechnology company’s stock valued at $3,783,000 after purchasing an additional 14,892 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Anavex Life Sciences during the 4th quarter worth $967,000. Finally, Franklin Resources Inc. boosted its holdings in shares of Anavex Life Sciences by 6.7% in the 3rd quarter. Franklin Resources Inc. now owns 58,557 shares of the biotechnology company’s stock worth $317,000 after buying an additional 3,674 shares during the last quarter. Hedge funds and other institutional investors own 31.55% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. D. Boral Capital restated a “buy” rating and set a $46.00 price objective on shares of Anavex Life Sciences in a report on Monday, April 7th. HC Wainwright reissued a “buy” rating and set a $42.00 target price on shares of Anavex Life Sciences in a research report on Monday, April 7th.

Anavex Life Sciences Price Performance

Shares of AVXL opened at $8.86 on Friday. Anavex Life Sciences Corp. has a 1 year low of $3.25 and a 1 year high of $14.44. The stock’s fifty day moving average price is $8.70 and its two-hundred day moving average price is $8.52. The firm has a market cap of $753.67 million, a PE ratio of -16.11 and a beta of 0.80.

Anavex Life Sciences (NASDAQ:AVXL) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03. Sell-side analysts anticipate that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current fiscal year.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.